Clinical trial · Observational
Permission to Collect Blood Over Time for Research
Predicting DVT Risk in GI Cancer Patients Using Plasma Biomarkers
NCT00767234CI-TRIAL-00022948terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Accrual issues - Low Accrual
Summary
Brief summary (as posted)
To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease. The ultimate goal of the study is to identify key biomarkers derived from blood that are most characteristic and informative of individuals who will go on to develop a clotting complication.
Conditions
Conditions (14)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Cancer | Malignant Anal Neoplasm | CURATED_EXACT | 0.92 |
| Bile Duct Carcinoma | Cholangiocarcinoma | ALIAS | 0.90 |
| Carcinoma of the Large Intestine | — | UNRESOLVED | — |
| Colon Rectal Cancer Adenocarcinoma | — | UNRESOLVED | — |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Gall Bladder Cancer | — | UNRESOLVED | — |
| Gallbladder Carcinoma | Gallbladder Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Gastric (Stomach) Cancer | Childhood Gastric Carcinoma | ALIAS | 0.90 |
| Gastrointestinal Neoplasms | Digestive System Neoplasm | ALIAS | 0.90 |
| Gastrointestinal Stromal Tumor (GIST) |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Identify Biomarkers
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female, \>= 18 years old. There are no ethnic restrictions. * Active cancers of the GI tract (gastroesophageal, colorectal, or pancreatic-biliary) that have completed TNM staging by the American Joint Committee on Cancer; stage III disease if diagnosed within 2 months and all stage IV disease * Ability to understand and the willingness to sign a written informed consent document. * Existing staging CT imaging study Exclusion Criteria: * Life expectancy \< 6 months * History of deep vein thrombosis (DVT) or pulmonary embolism (PE) * Known pregnancy or positive urine pregnancy test in pre-menopausal women * On anticoagulant therapy (heparin, warfarin, direct thrombin inhibitors) * No CT imaging studies, or contraindications to undergoing CT imaging * Existing or anticipated need for a tunneled central venous catheter * Clinic visitation to Stanford Cancer center for secondary consultation purposes only * Inability to give informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.